Provectus Biopharmaceuticals, Inc.
PVCT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $617 | $558 | $989 | $0 |
| % Growth | 10.7% | -43.6% | – | – |
| Cost of Goods Sold | $7 | $1,699 | $64 | $94 |
| Gross Profit | $610 | -$1,142 | $925 | -$94 |
| % Margin | 98.8% | -204.8% | 93.6% | – |
| R&D Expenses | $1,994 | $1,749 | $2,389 | $2,608 |
| G&A Expenses | $3,150 | $1,305 | $2,025 | $2,055 |
| SG&A Expenses | $3,150 | $1,357 | $2,025 | $2,055 |
| Sales & Mktg Exp. | $0 | $51 | $0 | $0 |
| Other Operating Expenses | -$580 | -$1,339 | -$1,023 | -$27 |
| Operating Expenses | $4,565 | $3,474 | $3,391 | $4,636 |
| Operating Income | -$3,955 | -$2,901 | -$3,428 | -$4,672 |
| % Margin | -640.8% | -520.2% | -346.6% | – |
| Other Income/Exp. Net | -$817 | -$201 | -$127 | -$867 |
| Pre-Tax Income | -$4,771 | -$3,117 | -$3,555 | -$5,540 |
| Tax Expense | -$9 | -$16 | $0 | $0 |
| Net Income | -$4,733 | -$3,102 | -$3,554 | -$5,540 |
| % Margin | -766.9% | -556.2% | -359.3% | – |
| EPS | -0.011 | -0.007 | -0.009 | -0.016 |
| % Growth | -52.7% | 12.9% | 46.5% | – |
| EPS Diluted | -0.011 | -0.007 | -0.009 | -0.016 |
| Weighted Avg Shares Out | 419,810 | 419,508 | 419,470 | 408,223 |
| Weighted Avg Shares Out Dil | 419,810 | 419,508 | 419,470 | 408,223 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $164 | $0 |
| Interest Expense | $239 | $216 | $164 | $962 |
| Depreciation & Amortization | $7 | $9 | $64 | $94 |
| EBITDA | -$4,525 | -$2,892 | -$3,364 | -$4,623 |
| % Margin | -733.2% | -518.5% | -340.1% | – |